BCAB Key Statistics, Chart & Performance
The current stock price of BCAB is 0.2806 USD. In the past month the price decreased by -59.83%. In the past year, price decreased by -38.72%.
BCAB Technical Analysis
BCAB Financial Highlights
Over the last trailing twelve months BCAB reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 32.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -438.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCAB Forecast & Estimates
7 analysts have analysed BCAB and the average price target is 10.2 USD. This implies a price increase of 3535.07% is expected in the next year compared to the current price of 0.2806.
For the next year, analysts expect an EPS growth of 23.5% and a revenue growth -100% for BCAB
BCAB Ownership
About BCAB
Company Profile
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Company Info
BIOATLA INC
11085 Torreyana Road
San Diego CALIFORNIA 92121 US
CEO: Jay M. Short
Employees: 61
Phone: 18585580708
BIOATLA INC / BCAB FAQ
What does BIOATLA INC do?
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
What is the current price of BCAB stock?
The current stock price of BCAB is 0.2806 USD. The price decreased by -3.24% in the last trading session.
What is the dividend status of BIOATLA INC?
BCAB does not pay a dividend.
How is the ChartMill rating for BIOATLA INC?
BCAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the market cap for BIOATLA INC?
BIOATLA INC (BCAB) has a market capitalization of 16.50M USD. This makes BCAB a Nano Cap stock.
When does BIOATLA INC (BCAB) report earnings?
BIOATLA INC (BCAB) will report earnings on 2026-03-25, after the market close.
Can you provide the short interest for BCAB stock?
The outstanding short interest for BIOATLA INC (BCAB) is 8.25% of its float.